Prosthetic valve thrombosis (PVT) following mechanical heart valve replacement is a serious clinical condition, and although thrombolytic therapy with alteplase is widely accepted as first-line treatment, the role of tenecteplase remains unclear due to limited evidence. To address this gap, a study evaluated the safety and efficacy of tenecteplase compared with standard alteplase infusions in 83 patients with PVT, with a mean age of 39.6 years. The study found that tenecteplase demonstrated higher rates of complete thrombolytic success compared with alteplase (97.5% vs 81.5%; risk ratio 1.18).
Patients in the tenecteplase group also achieved greater success with the first dose and had shorter hospital stays (median 4.1 vs 6.5 days). Rates of major and minor adverse events were similar between the two groups. These findings suggest that tenecteplase may offer a safe and effective…
